|
|
 |
|
Viewing report
|
|
|
|
Biotech Life Sciences: A 20/20 Vision to 2020
Burrill & Company, April 2008, Pages: 404
Chapter 1: 20/20 Vision to 2020:
Our Vision
Healthcare
AgBio
The Global Scene
Business Models and Market Cap
Chapter 2: Industry Metrics:
2007 Snapshot
The Capital Markets
Financings
M&A/Partnering
Regulatory
Biofuels in the Melting Pot
Global Biotech Crop Area Increased
International
Burrill’s Predictions for Biotech in 2008
Chapter 3: Healthcare:
Pharma Readies for the Future
Modest Growth Predicted for Pharmaceutical Market
Mixed Year for Pharma and Biotech
Pharma’s Top-Selling Drugs Starting to Peak
Steady Growth for Biotech Drugs
Product Approvals
Selected Major Setbacks in 2007
Innovation Gap Still Wide
Healthcare Spending
Personalized Medicine
Investors Wowed by Personalized Medicine
Diagnostics Companies Have a Good Year
Companion Diagnostics
Reimbursement is Critical
Dx Attracts Venture Capital and Suitors
Chapter 4: Wellness:
Consumers Want a Quality Experience
Big Food Goes Healthy
Wall Street Performance
M&A
Investors Whet Their Appetite
The International Market
The Regulatory Arena
Wellness and Prevention: The New Watchwords of Healthcare
Nutrigenomics Advances Personalized Nutrition
Healthy Aging
Using Beauty Drugs and Foods to Slow the Advance of Time
Organic Becomes Mainstream
Targeting Obesity
Biotech and Pharma Weigh In
Functional Foods for Weight Control
Edible Remedies
Medical Foods and Plant-based Therapies
Functional Foods
Probiotics: Focus on Digestive Health
Supplements
Looking Ahead
Chapter 5: Emerging Technologies:
Technologies Impacting Healthcare
Systems Biology
From Sequences to Systems Biology
Systems Biology Alters Drug Development
Nanomedicine
Nanotubes
Nanowires
Nanodiagnostics
NIH Roadmap 2008
Human Microbiome Project
Epigenomics
The Quest for the $1,000 Genome
The X PRIZE
Human Whole-Genome Sequencing
Illumina Sequences Genome of African Male
Scientists Create First Synthetic Bacterial Genome
The Power of RNA
RNA Interference—Switching Genes Off
RNA Activation—Switching Genes On
MicroRNA—Great Potential in Diagnostics and Treatments
Gene Therapy
Genomics: Back on the Radar Screen
Chapter 6: Politics and Policy:
FDA Amendments Act: Higher Fees, Enhanced Safety
PDUFA IV: Booming User Fees
Trials Registry and Databank
Conflict of Interest Waivers
What We Talk About When We Talk About Preemption
Post-Vioxx: The Need for Improved Drug Safety
FDAAA and Safety
Medical Device User Fee and Modernization Act
Changing Landscape
Diagnostics and Devices
Genomics: The Future of Safety?
The Genomics and Personalized Medicine Act of 2007
Personalized Medicine Milestone: Warfarin
IVDMIAs: FDA Revises Draft Guidance
MammaPrint: The First
Report Roundup: Genetics Tests and Nanotech Draw Scrutiny from Federal Agencies
Other Device and Diagnostic News
Patents: Worrisome Patent Changes on the Horizon
In the Courts
New USPTO Rules
Patent Reform Legislation
Storm Warnings
Global Stem Cell Developments
Asia Moves Forward With Stem Cell Research
Other Stem Cell News
Asian Trends
An Overview of EU Developments
Chapter 7: Agbio:
The Gene Revolution Transforms the Green Revolution
Companies Drive Innovation
Monsanto: A Long List of Deals
Syngenta Goes East—To China and Australia
Dow Goes South—To Latin America
DuPont: Busy Globally
Brazil: A Growing Player
Transgenics Become Mainstream
Global Metrics
Countries Move to Develop Own GM Technology
US Farmers Embrace Transgenics
Genetic Modification Taking Root in Europe—Slowly
The Changing Regulatory Landscape
Enabling Technologies
RNA Interference as a Pesticide
Bioremediation
Enhancing the Nutritional Quality of Food
Molecular Breeding, a Next-Generation Technology
Plant-Made Pharmaceuticals Become a Reality
Transgenic Animals
Looking Ahead
Chapter 8: Industrial Biotech and Biofuels:
The New Bio-Economy
International Initiatives
The United States: the Energy Independence and Security Act of 2007
Corporate Developments
Companies Push into the Global Market
Oil Companies Get Green
Cleantech Fuels VC Interest
Alternative Energy Gets US Government Backing
Bioenergy
Ethanol
Cellulosic Ethanol/Biomass
Biodiesel
Algae: A Potential Next-Generation Feedstock
Using Synthetic Biology to Make Designer Microbes
Microbial Fuel Cells
Bioplastics
Integrated Biorefineries
Biochememicals
Looking Ahead
Chapter 9: International:
Europe
Denmark
Canada
Australia/New Zealand
China
Japan
Malaysia
India
Chapter 10: M&A/Partnering:
Activity Down
Select M&A Transactions
$5-Billion-plus Deals
$1-Billion-plus Deals
Specialty Sector Transactions
Cancer
Trends
Regional M&A
Partnering
Deal Activity
The Top
Regional Alliances
Analysis of Transactions
The Outlook to 2020
Chapter 11: Finance & Capital Markets:
No Shortage of Capital for Biotechs
Positive Year for Biotech IPOs
China Connection
Other IPO Winners
On the Runway
PIPEs—an Essential Vehicle for Biotech
Follow-Ons
Debt
Venture Capital at Record Levels
Positive Performance on Capital Markets
Billion-Dollar Club
Burrill Mid-Cap Index
Burrill Small-Cap Index
Creative Financing and Listing Alternatives
Euronext
Biotech Platform
Looking Ahead
Industry Financial Data Reconciliation
Companies Ranked by December 31, 2007 Market Cap
Companies in Alphabetical Order
Chapter 12: About Burrill & Company:
Burrill & Company
Venture Capital
International
Greater China Group
India Group
Japan Group
Latin America Group
Malaysia Group
Middle East Group
Advisory Boards
Large Corporate Limited Partners
Portfolio Companies
Private Equity
Merchant Banking
Media
Customers who bought this item also bought
Biotech 2009-Life Sciences: Navigating the Sea Change
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Personalized Medicine - Scientific and Commercial Aspects
Biomarkers and Tests for Pharma/ Biotech R&D – Companies Products and WW Market, 2006-2011
Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 2nd edition
Systems Biology in Biotech and Pharma: A New Paradigm for Innovation
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
China Biotech 2008
Dealmaking and Business Strategies in the Age of Personalized Medicine
Personalized Medicine
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics
Beyond The Blockbuster Drug: Strategies For Nichebuster Drugs, Targeted Therapies and Personalized Medicine.
|
|
|
|
